Mackenzie Financial Corp Buys New Stake in Certara, Inc. (NASDAQ:CERT)

Mackenzie Financial Corp acquired a new position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,676,238 shares of the company's stock, valued at approximately $17,852,000. Mackenzie Financial Corp owned 1.04% of Certara at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of CERT. Venturi Wealth Management LLC grew its stake in shares of Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock valued at $30,000 after buying an additional 2,509 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after purchasing an additional 1,047 shares during the last quarter. Johnson Financial Group Inc. bought a new position in shares of Certara during the 4th quarter valued at $47,000. Blue Trust Inc. lifted its stake in shares of Certara by 20.9% in the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock valued at $56,000 after purchasing an additional 822 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd boosted its holdings in Certara by 204.7% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock worth $58,000 after purchasing an additional 3,656 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.

Wall Street Analysts Forecast Growth

CERT has been the subject of a number of analyst reports. JMP Securities reaffirmed a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. William Blair restated a "market perform" rating on shares of Certara in a report on Thursday, February 27th. TD Cowen initiated coverage on Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 target price for the company. KeyCorp lifted their price target on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. Finally, Stephens reaffirmed an "overweight" rating and set a $17.00 price objective on shares of Certara in a report on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $15.67.

Certara Stock Performance

Shares of CERT stock traded down $0.01 during trading hours on Friday, reaching $11.39. 987,275 shares of the company's stock were exchanged, compared to its average volume of 1,342,245. The business has a fifty day moving average price of $11.86 and a 200-day moving average price of $11.79. The stock has a market capitalization of $1.85 billion, a P/E ratio of -56.95, a P/E/G ratio of 9.29 and a beta of 1.57. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a fifty-two week low of $8.64 and a fifty-two week high of $17.76.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.04. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. During the same quarter in the previous year, the firm posted $0.10 EPS. The business's revenue was up 9.7% compared to the same quarter last year. Analysts predict that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.